Showing results (211-220 of 241) with videos related to
Sort By:
Pageof 25
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialYi-Long Wu, Shun Lu, Ying Cheng, et al.Immunotherapy|July 19, 2023
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in AsiaYing Cheng, James Chih-Hsin Yang, Isamu Okamoto, et al.Journal of Evidence-Based Medicine|July 1, 2022
Malignancy risk stratification for solitary pulmonary nodule: A clinical practice guidelineBojiang Chen, Qianrui Li, Qiukui Hao, et al.Lung Cancer (Amsterdam, Netherlands)|March 15, 2021
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)Ying Cheng, Tony S Mok, Xiangdong Zhou, et al.Journal of Thoracic Disease|July 10, 2020
Expert consensus for diagnosis and treatment using medical thoracoscopy in ChinaFaguang Jin, Hongwu Wang, Qiang Li, et al.Critical Care Medicine|March 3, 2016
Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral PneumoniaBin Cao, Hainv Gao, Boping Zhou, et al.Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|January 11, 2016
A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumoniaYang Liu, Yingyuan Zhang, Jufang Wu, et al.The Lancet Regional Health. Western Pacific|January 6, 2025
Consensus on the lung cancer management after third-generation EGFR-TKI resistanceQing Zhou, Hongyun Zhao, Shun Lu, et al.The Lancet. Oncology|July 26, 2011
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Yi-Long Wu, Gongyan Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)Hongyun Zhao, Wenxiu Yao, Xuhong Min, et al.Pageof 25